Inclusion Criteria:

- Confirmed diagnosis of metastatic soft-tissue or bone sarcoma

- Ongoing complete response, partial response, or stable disease (RECIST) after a
minimum of 4 cycles (and maximum of 12 months) of any one first, second, or third
line of prior cytotoxic chemotherapy for metastatic disease

- Eastern Cooperative Oncology Group performance status of 0 or 1

- Adequate organ and bone marrow function

- Completed prior chemotherapy with last dose received at least 3 and up to 12 weeks
prior to randomization

Exclusion Criteria:

- Prior therapy with rapamycin or rapamycin analogs

- Ongoing toxicity associated with prior anticancer therapy

- Another primary malignancy within the past three years

- Concomitant medications that induce or inhibit CYP3A

- Significant, uncontrolled cardiovascular disease